Hot Products

Arnidiol
Catalog No: CFN93111

Arnidiol has anti-inflammatory activity, it possesses marked inhibitory activity against 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced inflammation in mice, the 50% inhibitory dose of these compounds with respect to TPA-inflammation (1 microgram) is 0.03-0.2 mg/ear. Arnidiol shows inhibitory effects against Epstein-Barr virus early antigen (EBV-EA) activation with potencies either comparable with or stronger than that of glycyrrhetic acid, a known natural anti-tumor-promoter; it also possesses a wide range of cytotoxicity against human cancer cell lines, with GI50 values (concentration that yields 50% growth) of mostly less than 6 microM.
Aromadendrene
Catalog No: CFN95074

Aromadendrene has significant antibacterial activity against the Gram-positive and Gram-negative bacteria.
Aromadendrin
Catalog No: CFN98736

Aromadendrin possesses anti-inflammatory, antioxidant, and anti-diabetic properties, it exhibits anti-inflammatory activity through the suppression of nuclear translocation of NF-κB and phosphorylation of JNK in LPS-stimulated RAW 264.7 macrophage cells. Aromadendrin treatment induces adipogenesis by increases in PPARγ2 expression, resulting in stimulation of glucose uptake and ameliorated insulin resistance, suggests that it may represent a potential therapeutic candidate for the management of type 2 DM. Aromadendrin has inhibitory activity on aldose reductase and the formation of advanced glycation end products.
Arteannuin A
Catalog No: CFN97308

Arteannuin A is a natural product from Artemisia annua.
Arteannuin B
Catalog No: CFN98807

Arteannuin B and artemisinic acid are biogenetic precursors of artemisinin, an important antimalarial produced by the herb Artemisia annua, they are active against different bacteria and certain fungal species. Arteannuin B has potential antimalarialand antitumor activity.
Artemether
Catalog No: CFN99184

Artemether is a novel sonosensitizer,which has neurotoxicity, anti-schistosomiasis, anticancer and antitumor activities. It is an antimalarial for the treatment of resistant strains of falciparum malaria.
Artemetin
Catalog No: CFN98731

Artemetin has anti-inflammatory, antioxidant and antiapoptotic activities, it protects endothelial function through the activation of ERK1/2 and Akt. Intravenous injection of Artemetin (0.75 mg/kg) significantly reduces the hypertensive response to angiotensin I while increases the average length of bradykinin-induced hypotension.
Artemisinic acid
Catalog No: CFN97276

Artemisinic acid, is the immediate precursor of the semi-synthesis artemisinin, could be a cost-effective, environmentally friendly, high-quality and reliable source of artemisinin. Artemisinic acid has a variety of pharmacological activity, such as antimalarial, anti-tumor, antipyretic, antibacterial, allelopathy and anti-adipogenesis effects. Artemisinic acid is a regulator of adipocyte differentiation and C/EBP δ expression, it inhibits adipogenic differentiation of hAMSCs through reduced expression of C/EBP δ; it inhibits melanogenesis through downregulation of C/EBP α-dependent expression of HMG-CoA reductase gene.
Artemisinin
Catalog No: CFN99011

Artemisinin is a sesquiterpene endoperoxide which is a potent antimalarial agent. Artemisinin is active against different bacteria and certain fungal species. It inhibits tumor necrosis factor-α-induced vascular smooth muscle cell proliferation.
Artepillin C
Catalog No: CFN70443

Artepillin C shows antioxidant, anti-angiogenesis, and anti-tumor activities; it also shows anti-inflammatory effects mediated, at least in part, by prostaglandin E2 and nitric oxide inhibition through NF-κB modulation. Artepillin C activates the immune system, and possesses direct antitumor activity. Artepillin C can suppress alloreactive CD4 T cell responses in vitro, so it could be used as a potential immunosuppressant, either solely or as adjunct agent in treating graft versus host disease. Artepillin C promotes adipocyte differentiation and glucose uptake in part by direct binding to PPARγ, which could be the basis of the pharmacological benefits of green propolis intake in reducing the risk of type 2 diabetes.